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Syncope Risk Stratif ication in
the Emergency Department
Giorgio Costantino, MDa,*, Raffaello Furlan, MDb
CASE HISTORY
An 89-year-old woman was seen at the
emergency department (ED) complaining of
a transient loss of consciousness. Her
daughter reported that she suddenly felt as
though she were going to die and then
suddenly passed out; consciousness was
regained after what was described as an
endless time, whereas weakness, lighthead-
edness, and nausea endured for several
hours. No additional symptoms, including
chest pain and dyspnea, were reported.
Physical examination was normal apart
from a known cardiac systolic murmur. The
electrocardiogram (ECG) confirmed a previ-
ously known atrial fibrillation with a ventric-
ular rate of 80 beats per minute. Blood
pressure was 130/80 mm Hg. Laboratory
tests were within the normal range. Her
past history was characterized by arterial
hypertension, depression, and a stroke,
with the stroke resulting in some memory
deficit. She was on warfarin, enalapril, and
citalopram.
During the previous 2 weeks, she had been to
the ED twice. The first time she was evaluated
because of a near syncope while seating after
dinner and, 1 week later, a sudden episode
with near-syncope symptoms prompted her
to go the ED. On both occasions, after a brief
observation, she was discharged from the ED
with a diagnosis of anxiety.
What steps should be taken to deal with a patient
presenting at the ED because of a transient loss of
consciousness?
THE FIRST STEP: IDENTIFYING PATIENTS WITH
SYNCOPE
To identify the patient with syncope, 3 major
issues have to be addressed:
 Distinguish patients with syncope from
those with a transient loss of conscious-
ness (T-LoC) of nonsyncopal origin
 Differentiate patients with syncope from
those having falls
 Determine how to manage patients pre-
senting with near syncope
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KEY POINTS
 Identify syncope through a detailed history (whenever this is not feasible, any presumed transient
loss of consciousness should be considered and managed as syncope).
 Rule out syncope causes that may lead to a rapid clinical deterioration.
 Stratify patients according to risk (clinical judgment, a risk score, or a rule can be used). It is advis-
able to use the proposed criteria rather than a single anecdotal rule or risk score.
 Use monitoring procedures before deciding on hospitalization.
 Restrict the use of biomarkers to limited and specific cases.
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Distinguish Patients with Syncope from Those
with a T-LoC of Nonsyncopal Origin
Syncope is defined by the European Society of
Cardiology (ESC) guidelines as a T-LoC caused
by transient global cerebral hypoperfusion char-
acterized by rapid onset, short duration, and
spontaneous complete recovery.1 Therefore, syn-
cope must be differentiated from those situations
in which T-LoC is not induced by a global cerebral
hypoperfusion, as it is in the case of epilepsy,
hypoglycemia, stroke, and carbon monoxide
intoxication.
This pathophysiologic definition is important for
diagnostic and therapeutic purposes, but it is of
limited use in daily clinical practice because cere-
bral blood flow cannot be quantified during
syncope in every patient. Moreover, until a defini-
tive diagnosis is made, it is impossible to identify
the pathophysiologic mechanism underlying an
undetermined syncope, which accounts for up to
40% of all events.1,2
In keeping with a recent consensus study by Sun
and colleagues,3 we suggest a practical approach
that defines as syncope all T-LoC of presumptive
syncopal origin.
Differentiate Patients with Syncope from
Those Having Falls
In clinical practice, it is often impossible to differ-
entiate syncope and falls. Consider the case of
an 82-year-old woman who lives alone and is
found in the morning by her son on the floor,
having likely been there since the evening
before. Given that patients are seldom aware of
their transient loss of consciousness, in the
absence of a witness there is no way to discrim-
inate between a loss of consciousness caused
by syncope and one induced by a fall. This
concept highlights the crucial role played by
a careful history taken from a witness in facili-
tating the diagnosis during the early evaluation
in the ED.
In keeping with these considerations, when-
ever it is impossible to discriminate between
syncope and fall, any T-LoC should initially be
considered and managed as syncope, because
of its potential adverse outcome. Thereafter the
patient should enter the risk stratification
process followed by a careful cost benefits
evaluation. This latter must always be done
before any therapeutic option is started, par-
ticularly when potential significant side effects
may take place, such as in the case of pace-
maker or implantable cardioverter-defibrillator
(ICD) implants.
Determine how to Manage Patients
Presenting with Near Syncope (Presyncope)
At present, the management of patients with pre-
syncope is largely heterogeneous worldwide.3,4
Presyncope (or near syncope) refers to the feeling
of impending LoC without losing consciousness.
Several symptoms and physical signs contribute
to this subjective feeling, including weakness,
lightheadedness, tunnel vision, dizziness, nausea,
sweating, and pallor.
Because near syncope can be an indistinct con-
dition and because it is often assumed that its
prognosis is better than that of syncope, many
studies on syncope performed in the ED excluded
patients with presyncope at enrollment.5–7 In con-
trast, other investigators8 assumed that syncope
and near syncope were identical. To answer this
question, Grossman and colleagues4 compared
the clinical outcome of patients with presyncope
with that of individuals with syncope and found
no difference. The investigators concluded that
the prognosis of near syncope was similar to that
of syncope, but this statement has been ques-
tioned9–11 and data are not available from which
to draw definitive conclusions.
Based on these considerations and on the lack
of evidence, a physician should judge case by
case whether a presyncope episode ought to be
considered as a syncope.
It cannot directly be concluded that the
89-year-old patient discussed earlier has syn-
cope (according to the ESC definition, a T-LoC
caused by a global cerebral hypoperfusion).
That episode can be considered a T-LoC of
presumptive syncopal origin, and the patient’s
past history had no diabetes or epilepsy to
suggest a T-LoC of nonsyncopal origin. She did
not fall, because the daughter ruled out this
possibility. In addition, in our opinion, in the pres-
ence of risk factors (age, sudden syncope
without preliminary symptoms, abnormal ECG),
the 2 previous presyncope episodes should be
regarded as syncope.
THE SECOND STEP: RULING OUT CAUSES OF
SYNCOPE THAT MAY LEAD TO A RAPID
CLINICAL DETERIORATION
The overall risk for a patient entering the ED
because of syncope is between 5% and 15%,
and the mortality at 1 week is about 1%.5,7,8,10,11
The primary goal of the ED physician is thus to
discriminate individuals at low risk who can be
safely discharged, from patients at high risk who
require prompt hospitalization for monitoring
and/or appropriate treatment.
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Once a subject has been identified as having
had syncope, the diseases potentially leading to
a rapid clinical deterioration should be ruled out
(Box 1). See the articles as discussed by Krahn
and colleagues elsewhere in this issue.
THE THIRD STEP: STRATIFYING THE PATIENT
WITH SYNCOPE ACCORDING TO RISK
Undetermined syncope is common after the first
assessment in the ED. Thus, in the absence of
a positive diagnosis, the doctor’s main goal should
shift from the effort to further identify a syncope
cause to an attempt to stratify the patient risk.
This stratification can be done from the patient’s
history and the characteristics of the syncope.
Risk stratification can be obtained from clinical
experience (clinical judgment) or by using appro-
priate rules or risk scores. Rules or risk scores
may help the ED physician in decision making,
although so far there is no compelling evidence
that any score or rule performs better than
personal clinical judgment in affecting patients’
clinical outcomes.10–14
Rules
Rules were developed to stratify the risks of a single
patient presenting for syncope in the ED. Most
rules were obtained and derived in the ED setting
and are intended to assess short-term outcomes.
Rules encompass the presence or absence of
different dichotomous variables as risk factors. If
a single variable is present, then the patient is strat-
ified as high risk and requiring hospital admission.
Examples of such rules are the risk stratification
of syncope in the emergency department (Rose),
San Francisco Syncope Rule (SFSR), and Boston
Syncope Rules,7,8,15 with the SFSR8 being the
only rules that are externally validated.
SFSR
The SFSRwas first published in 2004 byQuinn and
colleagues8 based on 684 subjects seen for
syncope or near syncope in the ED. The investiga-
tors found that the presence of any of the variables
summarized in Table 1 had a sensitivity of 96%
(95% confidence interval [CI] 92%–100%) and
a specificity of 62% (95% CI 58%–66%) for pre-
dicting adverse events at 1-week follow-up.
Death, myocardial infarction, arrhythmia, pulmo-
nary embolism, stroke, subarachnoid hemor-
rhage, significant hemorrhage, or any condition
causing or likely to cause a new clinical evaluation
at ED or a new hospitalization for a related event
were considered adverse events. The SFSR has
been validatedby the same investigators in a sepa-
rate cohort of 791 patients, obtaining a sensitivity
of 98% (95% CI 89%–100%) and a specificity of
56% (95% CI 52%–60%) for adverse events at
30-day follow-up.16 The use of this rule would
have resulted in a 7% potential reduction of
hospital admissions (Tables 2 and 3).
Since its first reports, the SFSR has been exter-
nally validated by other investigators, with discor-
dant results.10,17–19 These inconsistencies might
be related to the heterogeneous ECG interpreta-
tion characterizing those studies.10 For example,
Quinn and colleagues20,21 considered as an ab-
normal ECG any new alteration, including the
Box 1
Potential life-threatening disorders leading to
syncope
Cardiovascular
Arrhythmias
 Ventricular tachycardia
 Bradycardia: Mobitz type II or third-
degree heart block
 Significant sinus pause (>3 seconds)
ECG features that can suggest an arrhythmic
origin
 Long QT syndrome
 Brugada syndrome
Ischemia
 Acute coronary syndrome, myocardial
infarction
Structural abnormalities
 Valvular heart disease: aortic stenosis,
mitral stenosis
 Cardiomyopathy (ischemic, dilated,
hypertrophic)
 Atrial myxoma
 Cardiac tamponade
 Aortic dissection
Significant hemorrhage
 Trauma with significant blood loss
 Gastrointestinal bleeding
 Tissue rupture: aortic aneurysm, spleen,
ovarian cyst, ectopic pregnancy
 Retroperitoneal hemorrhage
Pulmonary embolism
 Saddle embolus resulting in outflow tract
obstruction or severe hypoxia
Subarachnoid hemorrhage
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Table 1
Features of different syncope risk stratification tools
Rule/Score Acronym Variables How Does It Work?
SFSR CHESS Congestive heart failure, history of:
Hematocrit <30%
ECG, abnormal
Shortness of breath
Systolic blood pressure at triage <90 mm Hg
Patient at high risk if a single
variable is present
Rose BRACES BNP level 300 pg/mL or bradycardia 50 in
ED or before hospital
Rectal examination showing fecal occult
blood (if suspicion of gastrointestinal
bleeding)
Anemia: hemoglobin 90 g/L
Chest pain
ECG showing Q wave (not in lead III)
Saturation 94% on room air
Patient at high risk if a single
variable is present
BOSTONa None I. Signs and symptoms of acute coronary
syndrome
II. Worrisome cardiac history
III. Family history of sudden death
IV. Valvular heart disease
V. Signs of conduction disease
VI. Volume depletion
VII. Persistent (>15 min) abnormal vital
signs in the ED without the need for
concurrent intervention such as
oxygen, pressor drugs, temporary
pacemakers
VIII. CNS
Patient at high risk if a single
variable is present
OESIL None History of cardiovascular disease
Abnormal ECG
Age >65 y
Absence of prodromal symptoms
Single factor counts as 1.
Sum 1 5 low risk;
sum >1 5 high risk
EGSYS None Palpitations preceding syncope (4 pts)
Heart disease, abnormal ECG, or both (3 pts)
Syncope during effort (3 pts)
Syncope while supine (2 pts)
Precipitating or predisposing factors, or both
(warm, crowded place/prolonged
orthostasis/fear-pain-emotion) (1 pts)
Autonomic prodromes (nausea/vomiting)
(1 pts)
Score 3 pts is considered
positive
Abbreviations: BNP, brain natriuretic peptide; EGSYS, Evaluation of Guidelines in Syncope Study; pts, points; OESIL, Osser-
vatorio Epidemiologico sulla Sincope del Lazio; ROSE, Risk Stratification of Syncope in the Emergency Department; SFSR,
San Francisco Syncope Rule.
a I: 1, complaint of chest pain of possible cardiac origin; 2, ischemic ECG changes (ST increase or deep [>0.1 mV] ST
depression); 3, other ECG changes (VT, VF, supraventricular tachycardia [SVT], rapid atrial fibrillation, or new [or not
known to be old] ST-T wave changes); 4, complaint of shortness of breath. II: 5, history of coronary artery disease,
including deep Q waves and hypertrophic or dilated cardiomyopathy; 6, history of congestive heart failure or left ventric-
ular dysfunction; 7; history of or current ventricular tachycardia, ventricular fibrillation; 8, history of pacemaker; 9, history
of ICD; 10, prehospital use of antidysrhythmic medication excluding b-blockers or calcium channel blockers. III: 11, family
history (first-degree relative) with sudden death, HOCM, Brugada syndrome, or long QT syndrome. IV: 12, heart murmur
noted in history or on ED examination. V: 13, multiple syncopal episodes within the last 6 months; 14, rapid heart beat by
patient history; 15, syncope during exercise; 16, QT interval >500 ms; 17, second-degree or third-degree heart block or
intraventricular block. VI: 18, gastrointestinal bleeding by Hemoccult or history; 19, hematocrit <30; 20, dehydration
not corrected in the ED per treating physician discretion. VII: 21, respiratory rate >24 breaths/min; 22, O2 saturation
<90%; 23, sinus rate <50 beats/min or sinus rate >100 beats/min; 24, blood pressure <90mmHg. VIII: 25, primary CNS event
(ie, SAH, stroke).
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ECG abnormalities observed during a patient’s
monitoring in the ED. In contrast, other studies
focused only on the ECG features obtained at
ED presentation. Sacillotto and colleagues10 as-
sessed the sensitivity and specificity of that rule
by a systematic review and reported a sensitivity
of 87% (95% CI 79–93) and a specificity of 52%
(95% CI 43–62). These investigators concluded
that the SFSR can be useful in the decision-
making process of admitting or discharging
patients from the ED for those patients with unde-
termined syncope after ED evaluation. They
concluded that a posttest probability of adverse
events lower than 2% would be suitable to safely
discharge patients. However, this conclusion is
arbitrary because it does not take into account
that the exclusion of the dangerous causes of
syncope during the ED stay may reduce the likeli-
hood of adverse events more than the reduction
caused by a good performance of the rule. In addi-
tion, the SFSR did not provide clues to the clinical
features of patients who should undergo contin-
uous cardiovascular and respiratory monitoring.
The Rose rule
The Rose rule was published in 2010 and was
derived and validated in a single ED center in
Edimburgh.7 Reed and colleagues7 recruited 550
patients for deriving and 550 individuals for vali-
dating the rule and observed that the presence
of at least 1 of the proposed variables (risk factors)
had a sensitivity of 87% and a specificity of 66%
for adverse events (see Tables 1–3). Adverse
events included acute myocardial infarction, life-
threatening arrhythmias (ventricular fibrillation,
sustained, ventricular tachycardia, ventricular
pause >3 seconds), pacemaker or cardiac defi-
brillator implant within 1 month from the index
syncope, pulmonary embolism, cerebrovascular
accidents, intracranial or subarachnoid hemor-
rhage, hemorrhage requiring more than 2 units of
blood transfusion, acute surgical procedures, or
endoscopic intervention (see Table 2).
The limits of this rule are the poor sensitivity
found during the internal validation and the need
of a laboratory test (ie, B-type natriuretic peptides
[BNP]). This latter limitation implies that all patients
presenting in the ED for syncope should have
bloods taken, thus partially diverging from the
ESC syncope guideline suggestions1 and every-
day clinical practice. Moreover, no external valida-
tion of the rule is available at the moment.
The Boston Syncope Rule
The Boston Syncope Rule was first published in
2007 by Grossman and colleagues.15 The investi-
gators recruited 362 patients and considered the
variables (risk factors) reported in the American
College of Emergency Physicians’ clinical policy
on syncope.22 Given the presence of at least 1 of
the variables, the sensitivity and specificity of the
rule was 97% (95% CI 93–100) and 62% (95%
CI 56–69), respectively (see Tables 1–3).
Its complexity is the major weakness of this rule
because more than 10 variables should be consid-
ered. In addition, some variables, such as primary
central nervous system (CNS) events are adverse
events themselves. This weakness does not help
physician to decide which patient deserves closer
observation, monitoring, or hospital admission,
Table 2
Features of the studies leading to a risk stratification tool and its external validation
Rule/
Score
Derivation
Population
Validation
Population Setting; Follow-up External Validation
SFSR 684 syncope or
near syncope
791 patients with
syncope or near
syncope
ED; derivation 7 d,
validation 30 d
Systematic review:
sensitivity 87% (95%
CI 79–93), and
specificity of 52%
(95% CI 43–62)10
Rose 550 patients 550 patients ED; 30 d None
BOSTON None 362 patients ED; 30 d None
OESIL 270 patients in EDs,
1-y follow-up
328 patients,
1-y follow-up
ED; 1 y Few studies12
EGSYS 260 patients 258 patients ED; diagnosis of
cardiac syncope
on a predefined
diagnostic item;
mortality at 2 y
None
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Table 3
Adverse events and ECG features taken into account by the different risk stratification tools
Rule/Score Anomalous ECG Adverse Events
SFSR Any new change
In the absence of a previous ECG, any
abnormality during ECG repetition or
monitoring
Death, myocardial infarction, arrhythmias,
pulmonary embolism, stroke,
subarachnoid hemorrhage, significant
hemorrhage, or any condition causing or
likely to cause a return to ED and
hospitalization for a related event
Rose Q wave (not in lead III) Acute myocardial infarction according to
the universal definition, life-threatening
arrhythmias (ventricular fibrillation,
sustained ventricular tachycardia,
ventricular pause >3 s), pacemaker or
cardiac defibrillator implant within 1 mo
of index collapse, pulmonary embolus,
cerebrovascular accident, intracranial
hemorrhage, or subarachnoid
hemorrhage, hemorrhage requiring
a blood transfusion of 2 units, acute
surgical procedure, or endoscopic
intervention
BOSTON QT interval >500 ms
Second-degree or third-degree heart block
or intraventricular block
Ischemic ECG changes (ST increase or ST
depression [>0.1 mV])
Other ECG changes (VT, VF, SVT, rapid atrial
fibrillation, or new [or not known to be
old] ST), T wave changes, deep Q waves
The sinus rate <50 beats/min or sinus
rate >100 beats/min
Pacemaker/implantable cardiac
defibrillator placement, percutaneous
coronary intervention, surgery, blood
transfusion, cardiopulmonary
resuscitation, alterations in
antidysrhythmic therapy, endoscopy
with intervention, or correction of
carotid stenosis, death, pulmonary
embolus, stroke, severe infection/sepsis,
ventricular dysrhythmia, atrial
dysrhythmia (including SVT and atrial
fibrillation with rapid ventricular
response), intracranial bleed,
hemorrhage, myocardial infarction,
cardiac arrest, or life-threatening
sequelae of syncope (ie, rhabdomyolysis,
long bone or cervical spine fractures)
OESIL Rhythm abnormalities (atrial fibrillation or
flutter, SVT, multifocal atrial tachycardia,
frequent or repetitive premature
supraventricular or ventricular
complexes, sustained or nonsustained
ventricular tachycardia, paced rhythms)
Atrioventricular or intraventricular
conduction disorders (complete
atrioventricular block, Mobitz I or
Mobitz II atrioventricular block, bundle
branch block or intraventricular
conduction delay)
Left or right ventricular hypertrophy; left
axis deviation
Old myocardial infarction, ST segment and
T wave abnormalities consistent with or
possibly related to myocardial ischemia
Death at follow-up
(continued on next page)
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because in the presence of an acute cerebral
hemorrhage it is self-evident that hospital admis-
sion is mandatory.
Scores
Although rules consider the presence of a specific
variable sufficient to put the patient in a high-risk
class, scores incorporate several variables. These
variables are combined to derive a score that
enables the prediction of the subsequent risk to
the patient.
The scores were built up mostly by cardiologists
and are typically aimed at identifying cardiac
adverse events. This article discusses the Osser-
vatorio Epidemiologico sulla Sincope del Lazio
(OESIL) and the EGSYS risk scores.
OESIL risk score
OESIL was published in 200323 based on a deriva-
tion cohort in which Colivicchi and colleagues23
recruited 270 patients presenting to ED for
syncope. The validation cohort was subsequently
based on 328 individuals. The data suggested
that the presence of anomalous ECG, absence of
presyncope symptoms, history of cardiovascular
disease, and age older than 65 years were the
risk factors associated with a poor prognosis at
1-year follow-up (see Tables 1–3). Later, the OESIL
risk score was externally validated using the
Short-Term Prognosis of Syncope (STePS)5 popu-
lation and compared with the SFSR by Dipaola
and colleagues.12 In the work by Dipaola and
colleagues,12 our group showed that the OESIL
risk score had a sensitivity of 88% (95% CI
70–98) and a specificity of 60% (95% CI 55–64),
and the SFSR 81% (95% CI 61–93) and 63%
(95% CI 58–67), in predicting an adverse outcome
within 10 days. The clinical judgment (ie, the
doctor’s decision to admit or discharge patients
from ED independently of any strict adherence to
predefined protocol or risk scores) had a sensitiv-
ity of 77% (95% CI 56–91) and a specificity of
69% (95% CI 64–73). The sensitivities of the 3
decision-making approaches were not significantly
different, but the SFSR and OESIL would have
recognized all 5 patients who died within 10
days from syncope, whereas the clinical judg-
ment missed 2 deaths. However, the numbers of
patients and eventswere inadequate to drawdefin-
itive conclusions. Although derived on events at 1
year, the OESIL risk score proved to be useful
even in the short-term risk stratification of patients
with syncope. Major limitations of OESIL result
from the small number of its independent valida-
tions, whereas its main strength is its simplicity,
which enables its use even by nurses triaging
patients with syncope.
EGSYS score
The EGSYS score was derived and internally vali-
dated by Del Rosso and colleagues.6 It is the only
score that considered as events the different
causes of syncope and it was specifically aimed
at identifying a cardiac cause of the syncopal
episode. The investigators reported that the score
is characterized by a sensitivity of 92% (95% CI
77–98) and specificity of 69% (95% CI 63–75).
There are no external validations of such a score,
Table 3
(continued)
Rule/Score Anomalous ECG Adverse Events
Evaluation of
Guidelines in
Syncope Study
(EGSYS)
Sinus bradycardia, atrioventricular
block greater than first degree,
bundle branch block
Acute or old myocardial infarction
Supraventricular or ventricular
tachycardia
Left or right ventricular hypertrophy,
ventricular preexcitation long QT,
and Brugada pattern
Diagnosis of cardiac syncope:
Mechanical cardiac syncope (severe
valvular stenosis, or other flow
obstruction, acute myocardial
ischemia)
Arrhythmic syncope (sinus bradycardia,
40 beats/min or repetitive sinoatrial
blocks or sinus pauses of 3 s; Mobitz 2
or advanced second-degree
atrioventricular block or third-degree
atrioventricular block; alternating
left and right bundle branch block,
pacemaker malfunction with cardiac
pauses, rapid paroxysmal
supraventricular or ventricular
tachyarrhythmias) electrophysiologic
study alterations
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particularly in the emergency setting, and, for this
reason, the score is likely to bemore useful in a car-
diologic setting than in the ED, where syncope
episodes induced by noncardiac diseases are
more frequent (see Tables 1–3).
Table 4 compares the strength and weakness of
different rules and scores used for syncope risk
stratification.
Let us try to stratify the risk after syncope of the
89-year-old patient discussed earlier, by using the
previously mentioned clinical rules and risk scores.
The patient would have been stratified as being
at significant risk, thus deserving hospital admis-
sion, according to the Rose rule (ECG positive),
OESIL risk score (ECG, age), EGSYS score (ECG
and cardiovascular history), and Boston (multiple
syncope, cardiac systolic murmur). In contrast,
at admission in the ED she would have been strat-
ified as being at low risk according to the SFSR.
However, her recurrence of syncope, age, and
cardiovascular history would make any physician
uncomfortable about an early discharge.
To make this evaluation easier for the reader,
this article discusses the strengths and limitations
of the different rules or risk scores in Table 4.
The hospitalization rates related to syncope vary
widely worldwide, ranging from 15% to 65%.2 This
variation may be secondary to the differing organi-
zation of health care systems; to the consequent
different patients’ health care patterns; to the avail-
ability of both inpatient and outpatient facilities for
prompt syncope diagnosis and therapy, such as
those provided by a syncope unit24; and to physi-
cians’ personal knowledge of this disorder and
awareness of guidelines and clinical risk scores.
A recent investigation14 emphasized the lack
of evidence that syncope decision rules might
improve syncope diagnostic accuracy or reduce
work-up costs, thus challenging their usefulness.
A new tool for syncopemanagement is represented
by the syncope unit,24 in which differing medical
competence and several facilities are functionally
combined, as discussed in a dedicated article
elsewhere in this issue. Fig. 1 shows a flow diagram
of a possible syncope approach in the ED.
Do any of the risk rules or scores identify people
who might have adverse outcomes caused by
syncope, or do they simply identify people who
will have an adverse outcome and happen to
have syncope?
Based on our previous observations,5 there are
2 clinically important time frames for syncope.
The early period (hours and days) following
syncope characterized by the largest mortality
because of a new and still undiagnosed life-
threatening disorder leading to syncope, and
a second period characterized by a time scale of
months or years in which comorbidity and frailty
play amajor role. Because there is a low rate of ad-
verse events following syncope, the risk scores
and clinical rules are likely to better identify frailty
than patients’ short-term risk, which might
account for the poor performance of the rule/
scores in identifying short-term adverse clinical
outcomes.10–12
Based on these considerations, the role of clin-
ical decision rules or risk scores and their compar-
ison with clinical judgment in the management
of patients presenting in the ED for syncope
remain to be elucidated. In addressing syncope,
risk scores and decision rules can be useful by
highlighting the critical variables that should be
considered and we expect that the international
single-patient meta-analysis currently in progress
will provide a tentative answer to these issues.
Table 4
Comparison of different rules/risk scores
Rule/Score Strengths Limitations
SFSR User friendly
Derived in the ED
All adverse events considered
Several external validations
Inconsistency in validations results
Decision of patients monitoring at physician’s
discretion
Rose User friendly
Derived in the ED
All adverse events considered
Need venous sample
Not externally validated
Limited sensitivity compared with other rules
BOSTON Derived in the ED
All adverse events considered
Complicated
Overlap between risk factors and adverse events
OESIL User friendly Not derived in the ED
EGSYS User friendly
Considered cardiac cause of syncope
Not derived in the ED
Not consider all adverse events
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DOES HOSPITAL ADMISSION AFFECT
SYNCOPE PROGNOSIS?
Difficulties in promptly addressing the cause of
syncope in the emergency setting and concerns
about fatal arrhythmias and sudden death often
lead to an excessive hospital admission rate,
with increasing costs.2 For this reason, whether
or not hospital admission significantly affects the
outcome is an important issue.
The STePS study performed by our group
specifically addressed this topic5 and included
676 consecutive patients who presented for
syncope in 4 EDs. Both short-term (ie, within 10
days) and long-term (ie, within 1 year) adverse
events were assessed and compared in admitted
Fig. 1. Syncope diagnostic and risk stratification flow chart.
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and discharged patients, and the main variables
(risk factors) associated with a poor prognosis
within 10 days from syncope were abnormal
ECG, concomitant trauma, absence of symptoms
of impending syncope, and male sex. Those vari-
ables differed from the risk factors associated
with adverse prognosis in the long term, which
were age older than 65 years, history of neoplasm,
cerebrovascular disease, structural heart disease,
and ventricular arrhythmia. Although the number
of major therapeutic procedures (ie, pacemaker
or implantable cardioverter-defibrillator implants,
intensive care unit admission, cardiopulmonary
resuscitation maneuvers) was significantly higher
in admitted than in discharged patients, mortalities
were similar in both groups, and all subjects who
underwent major procedures could subsequently
be discharged. Taken together, these observa-
tions suggest that hospital admission may have
ameliorated the short-term clinical outcome of
patients with syncope, possibly because of the
lifesaving measures (ie, the major therapeutic
procedures) that could readily be carried out.
However, admitted patients had a worse 1-year
prognosis compared with their discharged coun-
terparts, possibly secondary to enhanced rates
of coexisting conditions (Fig. 2). Thus, in the long
term, comorbidities, rather than syncope, play
a crucial role in affecting 1-year prognosis. In the
long term, syncope could be considered as an
expression of the frailty of the patient, which may
represent one of the main problems to be faced
whenever rules and scores are used for syncope
risk stratification. Because of the paucity of deaths
and adverse events following syncope in the short
term, most of the risk scores and few of the clinical
rules have been derived or validated in the middle
period (ie, between 30 days and 1 month from the
event). Thus, rules are likely to better address the
frailty of the patient with syncope, whereas, in
the short term, they may be unable to identify
patients in whom syncope is the epiphenomenon
of a potentially life-threatening disease.
We conclude that hospitalization is definitively
useful in patients who need close monitoring or
are likely to undergo major therapeutic proce-
dures. Based on the observation that the 48 hours
following syncope present the highest risk for
death,5 continuous cardiorespiratory monitoring
for at least 48 hours, rather than a prolonged hospi-
talization, is likely to favorably affect the prognosis.
WHAT IS THE ACCEPTABLE RISK OF ADVERSE
EVENTS IN A DISCHARGED PATIENT WHO
HAD SYNCOPE?
Usefulness of syncope risk stratification as a clin-
ical tool for ED physicians can be evaluated ac-
cording to 2 different approaches:
1. By comparing syncope risk scales with simple
clinical judgment and verifying that the overall
performance of a specific risk score is higher
than that of the physician decision-making
process. Its application may result in safer and
more specific clinical management for the
patient with syncope.
2. An acceptable risk threshold has to be set. Ac-
cording to clinical rules, major events and death
risk have to be addressed in a subject who is
about to be discharged from the ED. Thereafter,
a clinical rule could be safely used whenever the
overall risk is lower than the value of the prede-
fined risk threshold. However, because the risk
of death and major clinical events from syn-
cope is low (0.7% and 5.4%, respectively),5 an
Fig. 2. Survival curves of admitted and discharged patients enrolled in the STePS study. Note that discharged
patients had lower long-term mortality than admitted individuals. (Modified from Costantino G, Perego F,
Dipaola F, et al. Short- and long-term prognosis of syncope, risk factors, and role of hospital admission: results
from the STePS (Short-Term Prognosis of Syncope) study. J Am Coll Cardiol 2008;51:276–83; with permission.)
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acceptable risk is hard to define. Moreover,
there is no consensus about risk thresholds,
and different groups consider different thresh-
olds to be acceptable.10,25
ARE LABORATORY BIOMARKERS USEFUL FOR
ED CLINICAL DECISION MAKING?
The European syncope guidelines do not consider
routine tests, as assessed by a venous sample,
to be appropriate for syncope evaluation in all
patients.1 However, D-dimer and other biomarkers
have attracted interest for risk stratification in the
ED.
D-Dimer
There is evidence that the routine measurement
of D-dimer in patients presenting to the ED for
syncope is useless both for identifying the cause
of syncope and as a prognostic index.26 D-dimer
may have a significant role in selected syncope
cases in which there is significant suspicion for
pulmonary embolism or aortic dissection.27
Troponin
There is evidence that routine measurement of
troponin is of limited effectiveness in the ED man-
agement of the patient with syncope, although it
can be useful in selected cases in which acute
coronary syndrome is suspected.28 There are no
conclusive dataon theuseof ultrasensitive troponin
assays.
BNPs
N-Terminal pro–brain natriuretic peptide (NT-
proBNP) and BNP have been used to assess the
prognosis and cause of syncope. In the Rose deci-
sion rule,7 the plasma BNP level was proposed as
a reliable marker for syncope risk stratification. In
addition, BNP was recommended to discriminate
cardiac and noncardiac causes of syncope.
Increased BNP and NT-proBNP plasma levels
have been observed in arrhythmias and these
peptides have thus raised interest as biomarkers
of arrhythmic syncope.29 Pfister and colleagues30
suggested the use of NT-proBNP to differentiate
arrhythmic from nonarrhythmic syncope. However,
a single BNP assessment is largely influenced by
comorbidities31 and we reported32 that the time
course of BNP and NT-proBNP changes following
an induced ventricular fibrillation had a peak of
increase of both biomarkers 9 hours after the event.
These data suggested that the use of BNP kinetics,
rather than single plasma measurements, could be
useful both to identify a potential arrhythmic cause
of syncope and for patient risk stratification, but
prospective studies are expected to confirm this
hypothesis.
The 89-year-old patient discussed earlier felt
that she was going to die during ECG continuous
monitoring in the ED. The ECG showed a 4-second
pause. A permanent pacemaker was placed and,
so far, the patient has not had another syncope
spell.
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